In trial, prioritised, and non-prioritsed interventions

In trial

Simvaststain

First reviewed: April 2023     In trial: tbc

Simvastatin competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis.

Baricitinib

First reviewed: April 2023     In trial: tbc

Baricitinib selectively and reversibly inhibits the Janus-associated tyrosine kinases JAK1 and JAK2.

Prioritised

Atibuclimab

First reviewed: April 2023     Priority: 1

Atibuclimab (IC14) is a chimeric CD14 antibody

Complement inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

• Vilobelimab (a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma)

IL-6 receptor inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

• Tocilizumab

TNF-alpha inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

• Infliximab

Where there are multiple drugs in a class, the class is prioritised until the capacity exists for entry into the platform. At this point, a further exercise is undertaken to decide on the specific drug to be taken forward.

Under review

Artesunate

First reviewed: August 2023

Insufficient evidence at this time.

CRAC channel inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Auxora (CM4620)

Furosemide

nebulised/inhaled

First reviewed: April 2023

Insufficient evidence at this time.

Galectin-3 inhibitors

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Belapectin (nebulised/inhaled)

Macrolides

First reviewed: April 2023

Insufficient evidence at this time.

p38 MAPK inhibitors

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Dilmapimod

PSCK9 inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Neutrophil elastase inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Sivelestat

Sphingosine 1-phosphate receptor modulators

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Fingolimod

Tyrosine kinase inhibitors

Reviewed: 24-04-2023

Insufficient evidence at this time.

Specific drugs considered to date:

• Imatinib.

Not prioritised

Aspirin

Reviewed: 24-04-2023

Not prioritised on the basis of prevalence of use in the target population and poor recruitment in previous ARDS trials.

Citrulline

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.

Corticosteroids

Reviewed: 24-04-2023

Not prioritised on the basis of ongoing or proposed trials.

N-acetyl-cysteine

nebulised/inhaled

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.

Streptokinase

nebulised/inhaled

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.